A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

Completed · Phase 2

Conditions studied: Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin

In brief

This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.

Key facts

Study ID

NCT00947856

Run by

Seagen Inc.

People needed

110

Starts

2009-07-01

Expected to finish

2013-03-01

Last updated by the study team

2017-02-02

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participated in a previous brentuximab vedotin study.
• CD30-positive hematologic malignancy.
• At a minimum, experienced clinical benefit in the prior brentuximab vedotin study. For retreatment, patients must have previously achieved either complete or partial remission with brentuximab vedotin and experienced disease progression after discontinuing the prior brentuximab vedotin study.

You may not qualify if…

• Withdrew consent to participate in any prior brentuximab vedotin study.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• City of Hope National Medical Center — Duarte, California, United States
• Stanford Cancer Center — Stanford, California, United States
• Colorado Blood Cancer Institute — Denver, Colorado, United States
• University of Miami Miller School of Medicine / Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• Loyola University Medical Center - Cardinal Bernadin Cancer Center — Maywood, Illinois, United States
• St. Francis Medical Group Oncology & Hematology Specialists — Indianapolis, Indiana, United States
• Karmanos Cancer Institute / Wayne State University — Detroit, Michigan, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• The John Theurer Cancer Center, Hackensack University Medical Center — Hackensack, New Jersey, United States
• NYU Clinical Cancer Center — New York, New York, United States
• Columbia University Medical Center — New York, New York, United States
• Nationwide Children's Hospital — Columbus, Ohio, United States
• Charles A. Sammons Cancer Center — Dallas, Texas, United States
• MD Anderson Cancer Center /The University of Texas — Houston, Texas, United States
• Seattle Cancer Care Alliance / University of Washington Medical Center — Seattle, Washington, United States
• Hopital Saint-Louis/Service d'Hematologie — Paris, Cedex 10, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.